Search research articles
Contact Us
Filters
Showing results (111-120 of 183) with videos related to
Page
of 19
Sort By:
Molecular Pharmaceutics
|
September 22, 2018
Preclinical Efficacy and Characterization of Candidate Vaccines for Treatment of Opioid Use Disorders Using Clinically Viable Carrier Proteins
Federico Baruffaldi, April Huseby Kelcher, Megan Laudenbach, et al.
Clinical and Vaccine Immunology : CVI
|
May 14, 2010
Functional T-cell deficiency in adolescents who experience serogroup C meningococcal disease despite receiving the meningococcal serogroup C conjugate vaccine
Rachel A Foster, Jennifer Carlring, Andrew Lees, et al.
Protein Expression and Purification
|
July 23, 2014
A scalable method for biochemical purification of Salmonella flagellin
Raphael Simon, Brittany Curtis, Vehid Deumic, et al.
Infection and Immunity
|
May 8, 2013
Novel synthetic (poly)glycerolphosphate-based antistaphylococcal conjugate vaccine
Quanyi Chen, Jay Dintaman, Andrew Lees, et al.
Plos One
|
February 21, 2012
Correlation of group C meningococcal conjugate vaccine response with B- and T-lymphocyte activity
James B Wing, Lynne Smart, Ray Borrow, et al.
Parkinsonism & Related Disorders
|
January 24, 2021
Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study
Regina Katzenschlager, Werner Poewe, Olivier Rascol, et al.
Journal of Neuroinflammation
|
October 1, 2008
Mannan-Abeta28 conjugate prevents Abeta-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice
Irina Petrushina, Anahit Ghochikyan, Mikayel Mkrtichyan, et al.
Journal of Parkinson'S Disease
|
March 26, 2014
Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease
Iciar Aviles-Olmos, John Dickson, Zinovia Kefalopoulou, et al.
Infection and Immunity
|
August 3, 2011
Salmonella enterica serovar enteritidis core O polysaccharide conjugated to H:g,m flagellin as a candidate vaccine for protection against invasive infection with S. enteritidis
Raphael Simon, Sharon M Tennant, Jin Y Wang, et al.
The Journal of Clinical Investigation
|
June 4, 2013
Exenatide and the treatment of patients with Parkinson's disease
Iciar Aviles-Olmos, John Dickson, Zinovia Kefalopoulou, et al.
Page
of 19
Search research articles
Search
Showing results (111-120 of 183) with videos related to
Sort By:
Page
of 19
Molecular Pharmaceutics
|
September 22, 2018
Preclinical Efficacy and Characterization of Candidate Vaccines for Treatment of Opioid Use Disorders Using Clinically Viable Carrier Proteins
Federico Baruffaldi, April Huseby Kelcher, Megan Laudenbach, et al.
Clinical and Vaccine Immunology : CVI
|
May 14, 2010
Functional T-cell deficiency in adolescents who experience serogroup C meningococcal disease despite receiving the meningococcal serogroup C conjugate vaccine
Rachel A Foster, Jennifer Carlring, Andrew Lees, et al.
Protein Expression and Purification
|
July 23, 2014
A scalable method for biochemical purification of Salmonella flagellin
Raphael Simon, Brittany Curtis, Vehid Deumic, et al.
Infection and Immunity
|
May 8, 2013
Novel synthetic (poly)glycerolphosphate-based antistaphylococcal conjugate vaccine
Quanyi Chen, Jay Dintaman, Andrew Lees, et al.
Plos One
|
February 21, 2012
Correlation of group C meningococcal conjugate vaccine response with B- and T-lymphocyte activity
James B Wing, Lynne Smart, Ray Borrow, et al.
Parkinsonism & Related Disorders
|
January 24, 2021
Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study
Regina Katzenschlager, Werner Poewe, Olivier Rascol, et al.
Journal of Neuroinflammation
|
October 1, 2008
Mannan-Abeta28 conjugate prevents Abeta-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice
Irina Petrushina, Anahit Ghochikyan, Mikayel Mkrtichyan, et al.
Journal of Parkinson'S Disease
|
March 26, 2014
Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease
Iciar Aviles-Olmos, John Dickson, Zinovia Kefalopoulou, et al.
Infection and Immunity
|
August 3, 2011
Salmonella enterica serovar enteritidis core O polysaccharide conjugated to H:g,m flagellin as a candidate vaccine for protection against invasive infection with S. enteritidis
Raphael Simon, Sharon M Tennant, Jin Y Wang, et al.
The Journal of Clinical Investigation
|
June 4, 2013
Exenatide and the treatment of patients with Parkinson's disease
Iciar Aviles-Olmos, John Dickson, Zinovia Kefalopoulou, et al.
Page
of 19